Droia Ventures

Droia invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients. We are specialists, investing exclusively in therapeutics for oncology and genetic diseases.

Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies’ progress by actively supporting them from company creation through clinical proof of concept. We are hands-on investors and entrepreneurs, fully dedicated to making an impact and saving patient lives.

For biotech companies, ultimate success is measured in effective patient benefit. Promising therapies should have a material impact on patient prognosis, measured as a function of the severity of the unmet medical need addressed and the improvement in therapeutic benefits as compared to the (expected) standard of care.

We only invest in companies that are able, through their technology platforms or scientific insights, to go after previously unsolvable clinical problems. Companies should differentiate not only by way of innovation but also by the way this innovation translates to clinical breakthroughs.

Droia actively scouts for the best science and the best teams. Whether investing in an existing company or creating a new company, we actively participate in our portfolio companies’ development. Our team has deep and specialized experience in disease biology, translational science, clinical development, and company building.

We have built many companies from the ground up, supporting and complementing founders and management teams. Our team members dedicate their time to helping their companies and will take on interim roles within companies to help them get off the ground faster. Our whole organization is geared towards doing what we do best: building great drug development companies.